SOURCE: ViaDerma, Inc.

November 21, 2017 08:12 ET

ViaDerma, Inc. is Granted Approval to sell VitaStem™ its FDA Registered Topical Antibiotic on and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products

ViaDerma's Manufacturer Delivered the first run of its topical antibiotic being sold as VitaStem by its Sales, Marketing and Distribution Partner Biogenx, Inc.; The Company will now start Producing New Products for Distribution in 400 Retail Stores in Canada for its CBD or Cannabinoids Product Line

LOS ANGELES, CA--(Marketwired - November 21, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has begun sales and distribution of its highly anticipated topical antibiotic ointment. Its marketing, sales and distribution partner, Biogenx, Inc. has been preselling the product, under the name of VitaStem™. Which now retails for $79 and can be purchased online at The Company plans to start manufacturing the second production run of the product and now has streamlined the manufacturing. The Company expects to ramp up production, monthly as the interested in the product continues to grow.

The Company will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.

The Company's President, Dr. Christopher Otiko said, "Now that we have streamlined the manufacturing process we are ramping up sales and distribution and expect the orders to come in from several key countries abroad. The quick response by customers in all our testing trials have shown positive results and this has led to an overwhelming interest in our products in several markets around the world. This has opened the door for future products in several key markets. Our contract manufacturer has now streamlined the process and has the capabilities to manufacture most of our products. We are now ready to start manufacturing several of our new products look forward to delivering several high-quality pharmaceuticals to our distributors."

About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's products use an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2017. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Crohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit:

Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.

Contact Information